Apellis Pharmaceuticals (APLS) News Today → BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad) Free APLS Stock Alerts $42.30 -1.60 (-3.64%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineApellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive Pressuresmarkets.businessinsider.com - May 8 at 7:40 PMApellis stock sell-off over Syfovre sales "overdone," says Citimsn.com - May 8 at 7:40 PMIn-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticalsmarkets.businessinsider.com - May 8 at 7:40 PMApellis Pharmaceuticals (NASDAQ:APLS) Given New $60.00 Price Target at Citigroupmarketbeat.com - May 8 at 4:48 PMApellis Pharmaceuticals' (APLS) Buy Rating Reaffirmed at HC Wainwrightmarketbeat.com - May 8 at 4:00 PMApellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Meets Estimatesmarketbeat.com - May 8 at 8:24 AMApellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - May 8 at 7:44 AMApellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports First Quarter 2024 Financial Resultsfinanznachrichten.de - May 7 at 9:43 PMAPLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024msn.com - May 7 at 4:36 PMApellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentationseekingalpha.com - May 7 at 4:03 PMApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81marketbeat.com - May 7 at 3:22 PMApellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04Mmsn.com - May 7 at 11:35 AMApellis Pharmaceuticals Reports First Quarter 2024 Financial Resultsglobenewswire.com - May 7 at 7:05 AMVictory Capital Management Inc. Has $36.89 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)marketbeat.com - May 7 at 5:53 AMApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLCmarketbeat.com - May 6 at 10:39 PMApellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conferenceglobenewswire.com - May 6 at 7:00 AMApellis Pharmaceuticals (APLS) to Release Quarterly Earnings on Tuesdayamericanbankingnews.com - May 5 at 5:20 AMCalifornia Public Employees Retirement System Sells 38,011 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)marketbeat.com - May 3 at 4:47 AMApellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meetingglobenewswire.com - May 1 at 7:00 AMApellis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:APLS)americanbankingnews.com - May 1 at 4:10 AMApellis Pharmaceuticals (NASDAQ:APLS) Sees Strong Trading Volumemarketbeat.com - April 30 at 5:34 PMApellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)marketbeat.com - April 30 at 2:43 PMApellis Pharmaceuticals stock falls following Mizuho comments, price target cutinvesting.com - April 30 at 1:14 PMA Closer Look at Apellis Pharmaceuticals's Options Market Dynamicsbenzinga.com - April 30 at 1:14 PMApellis Pharmaceuticals (APLS) Set to Announce Quarterly Earnings on Tuesdaymarketbeat.com - April 30 at 11:48 AMApellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $52.00 at Mizuhoamericanbankingnews.com - April 30 at 5:32 AMApellis Pharmaceuticals (NASDAQ:APLS) Shares Down 3.5% Following Analyst Downgradeamericanbankingnews.com - April 30 at 1:16 AMApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.5% After Analyst Downgrademarketbeat.com - April 29 at 10:59 AMApellis Pharmaceuticals (NASDAQ:APLS) Given New $52.00 Price Target at Mizuhomarketbeat.com - April 29 at 8:07 AMNew York State Common Retirement Fund Sells 62,437 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)marketbeat.com - April 28 at 6:16 AMApellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwrightamericanbankingnews.com - April 28 at 3:14 AMApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Up to $47.93americanbankingnews.com - April 28 at 2:34 AMApellis Pharmaceuticals (NASDAQ:APLS) Receives "Buy" Rating from HC Wainwrightmarketbeat.com - April 26 at 2:44 PMApellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)globenewswire.com - April 26 at 7:15 AMabrdn plc Acquires Shares of 169,051 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)marketbeat.com - April 26 at 6:13 AMApellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLCmarketbeat.com - April 25 at 1:39 PMZacks Research Comments on Apellis Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:APLS)marketbeat.com - April 25 at 8:47 AMApellis Pharmaceuticals, Inc. Expected to Earn Q2 2025 Earnings of $0.23 Per Share (NASDAQ:APLS)marketbeat.com - April 24 at 6:49 AMApellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Resultsglobenewswire.com - April 23 at 7:00 AMMackenzie Financial Corp Purchases Shares of 41,485 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)marketbeat.com - April 23 at 5:11 AMJennison Associates LLC Has $196.10 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)marketbeat.com - April 22 at 12:35 PMAllspring Global Investments Holdings LLC Reduces Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)marketbeat.com - April 21 at 4:36 AMWedbush Comments on Apellis Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:APLS)marketbeat.com - April 19 at 8:18 AMBehind the Scenes of Apellis Pharmaceuticals's Latest Options Trendsbenzinga.com - April 18 at 2:22 PMFY2025 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Reduced by Analystmarketbeat.com - April 18 at 6:48 AMApellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $57.00 at Wedbushmarketbeat.com - April 17 at 3:44 PMApellis Pharmaceuticals (NASDAQ:APLS) Shares Up 2.9%marketbeat.com - April 16 at 1:40 PMThe 5 Stocks Most Sold By Insiders This Year (APLS)insidertrades.com - April 16 at 10:45 AMApellis Pharmaceuticals (NASDAQ:APLS) Given "Buy" Rating at HC Wainwrightmarketbeat.com - April 15 at 8:16 AMApellis Pharmaceuticals executive sells over $3.7m in stockinvesting.com - April 11 at 7:42 AM Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address The Weight Loss Pill That Could Disrupt a $32 Billion Industry (Ad)A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results. Don't miss out on the "next Ozempic" >>> APLS Media Mentions By Week APLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.630.36▲Average Medical News Sentiment APLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼238▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BPMC News BBIO News OGN News IONS News PRGO News NUVL News CYTK News ALPN News ELAN News ALKS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
